Guangzhou Gloryren Medical Technology Co., Ltd. Solemn Statement
Gloryren Statement [2026] No.01
With respect to the Solemn Statement issued through its official channels by the INC International Neurosurgeon Group (hereinafter referred to as “INC”) on July 27, 2026, Guangzhou Gloryren Medical Technology Co., Ltd. (hereinafter referred to as “our Company”) hereby solemnly declares as follows in accordance with law:
I. The Publication of the Articles at Issue by Our Company Constituted Legitimate Public Opinion Supervision Undertaken to Safeguard the Public's Health Rights and Interests
On July 7 and July 14, 2026, our Company successively published two articles through its official WeChat account and official website, entitled “A Sky-High RMB 700,000 ‘Fly-in’ Surgery” and “RMB 820,000 Fly-in Surgery in Suzhou, China” (collectively, the “Articles at Issue”).
The Articles at Issue were intended to expose the objectively existing risks to patients’ life, health and property safety in the business model whereby “overseas surgeons come to China to perform surgery as the operating surgeon, while commercial entities circumvent medical institutions and charge patients exorbitant fees.” These matters concern the right of glioma patients and their families to make informed choices, as well as their significant property interests, and therefore constitute public opinion supervision involving a major public interest.
Pursuant to Article 1025 of the Civil Code of the People’s Republic of China, where an actor, in conducting news reporting, public opinion supervision or other similar activities for the public interest, affects another person’s reputation, the actor shall not bear civil liability, subject to the circumstances prescribed by law. The publication of the Articles at Issue by our Company therefore has a legal basis.
II. The Facts Stated in the Articles at Issue Are True and Supported by Evidence, and Were Neither Fabricated nor Distorted
(1) In 2024, Ms. Dong from Shanghai paid RMB 719,000 to a “Shanghai intermediary company.” In December 2025, Mr. Chen from Shangrao, Jiangxi, upon the recommendation of the “Prof. Xiao, Director of the Department of Neurosurgery of a Grade III Class A hospital in Suzhou” referred to in the Articles at Issue, entered into a contract with the Wuhan branch of the “Shanghai intermediary company” and paid RMB 820,000. In January 2026, a single-parent family in Taicang borrowed RMB 650,000 to pay RMB 820,000 for the patient’s treatment.
The above-mentioned patients or their family members have provided our Company with the relevant contracts, payment records, medical-treatment materials, and other supporting documents. The facts stated in the Articles at Issue are therefore supported by evidence.
(2) The statements cited in the Articles at Issue, including “more than 200 operations as the operating surgeon over seven years, with cumulative fees exceeding RMB 140 million,” were statements publicly published by the “Shanghai intermediary company” on its own WeChat official account. Our Company merely quoted and commented on such statements.
(3) The Articles at Issue expressed comments based on publicly available and verifiable information and facts reported by patients. They contained no insulting language and did not exceed the scope of legitimate public-opinion supervision and reasonable comment.
III. Organizing medical treatment and charging patients high fees without the requisite qualifications is suspected of violating the law and should properly be subject to public oversight
(1) Article 23 of the Regulations on the Administration of Medical Institutions provides that no entity or individual may conduct medical diagnosis and treatment activities without obtaining a Medical Institution Practicing License or completing the required filing. Article 99 of the Law of the People’s Republic of China on Basic Medical and Health Care and the Promotion of Health provides for administrative legal liability for unauthorized medical practice.
The “Shanghai intermediary company” and its affiliated companies, acting as commercial entities, organize surgeries and directly charge patients fees ranging from more than RMB 700,000 to RMB 850,000 per surgery. Whether they possess the requisite legal qualifications, on what basis such payments are collected, and how the funds are transferred and handled all concern significant public interests and should therefore be subject to public supervision and examination by the competent authorities.
(2) Articles 3 and 4 of the Interim Administrative Measures for Foreign Physicians Practicing Medicine in China on a Short-Term Basis provide that foreign physicians practicing medicine in China on a short-term basis must complete registration and obtain a Foreign Physician Short-term Practice Permit, and must have a medical institution in China as their inviting or employing entity.
The public has the right to know whether the relevant parties have completed the aforementioned procedures in accordance with the law.
(3) The Articles at Issue pointed out that the total cost of comparable surgery at a university-affiliated hospital in Germany is approximately EUR 40,000, which may be fully covered by statutory or private health insurance, while the remuneration received by the primary surgeon is only EUR 3,000 to EUR 5,000 per surgery. Against this background, the Articles at Issue questioned and criticized the charging of as much as RMB 820,000 to patients in China. Such comments did not exceed the scope of legitimate comment.
Our Company is currently compiling the relevant materials and will report the matter to the competent authorities, including the health authorities and market regulation authorities, in accordance with the law, and is willing to fully cooperate with any investigation.
IV. INC’s Solemn Statement has allegedly infringed upon our Company’s right to reputation, and our Company hereby demands that INC bear legal liability in accordance with the law
Without any effective judicial or other legally binding instrument having determined that our Company has committed an infringement, INC publicly accused our Company of “continuously disseminating false and untrue information,” “maliciously defaming the reputation of others,” and “having allegedly committed serious infringement,” and threatened to initiate judicial proceedings.
Such statements lack factual and legal basis and are sufficient to mislead the public and damage our Company’s reputation and business credibility. They are suspected of violating Articles 1024 and 1194 of the Civil Code of the People’s Republic of China and Article 11 of the Anti-Unfair Competition Law of the People’s Republic of China. Article 11 of the latter law provides that business operators shall not fabricate or disseminate false or misleading information for the purpose of damaging the business reputation or commodity reputation of a competitor.
Our Company hereby solemnly demands that INC:
(1) Immediately delete the Solemn Statement dated July 27, 2026, as well as the accusatory content consistent therewith published on all platforms, and cease infringing upon our Company’s right to reputation;
(2) Publicly clarify the facts within the same scope in which the original statement was published, apologize to our Company, and eliminate the adverse impact, with such clarification and apology remaining in place for no less than fifteen days;
(3) Immediately cease threatening to initiate litigation, intimidating patients and their families, and suppressing legitimate public-opinion supervision.
V. Our Company will pursue its lawful rights and interests to the end
Our Company has completed the preservation and securing of evidence concerning the relevant conduct of INC.
Should INC refuse to rectify its conduct, our Company will file a lawsuit with the People’s Court in accordance with the law, seeking that INC bear all corresponding civil liabilities, including cessation of the infringement, elimination of adverse effects, restoration of reputation, issuance of an apology, and compensation for losses.
Should the conduct be suspected of constituting the crime of damaging business reputation or commodity reputation, our Company will file a criminal complaint with the public security authorities in accordance with the law. Article 221 of the Criminal Law of the People’s Republic of China addresses the fabrication and dissemination of stories intended to damage another person’s business credit or commodity reputation.
A citizen’s right to health must never become an object of commercial transaction.
Our Company’s position of speaking out on behalf of patients and lawfully exercising oversight over misconduct in the medical sector will never change in response to any threat.
Patients, family members, medical professionals and persons with relevant knowledge are welcome to provide our Company with relevant information and leads.
This statement is hereby issued.
Declarant: Guangzhou Gloryren Medical Technology Co., Ltd.
September 19, 2026
